Insomnia in Long COVID: Prevalence, Neurological Associations, and Treatment Outcomes (Jan 2021– May 2025)

This dataset supports a systematic review and meta-analysis examining the prevalence, neurological associations, and treatment outcomes of insomnia in individuals with Long COVID (Post-Acute Sequelae of SARS-CoV-2 infection, or PASC). The analysis includes peer-reviewed studies published between January 2021 and May 2025, retrieved from PubMed, Scopus, and Web of Science. The data files include: Study selection criteria and methodology summaries Extracted data on insomnia prevalence across demographic and clinical subgroups Associations with cognitive dysfunction, autonomic dysregulation, and neuroinflammatory markers Effect size estimates for interventions including Cognitive Behavioral Therapy for Insomnia (CBT-I), melatonin supplementation, acupuncture, and pharmacological agents All methods were conducted in accordance with PRISMA 2020 guidelines. Risk of bias was assessed using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias tool. Meta-analyses were performed using random-effects models. This resource is intended to support clinicians, researchers, and public health professionals in understanding and treating insomnia as a persistent symptom of Long COVID.